Going against tradition


When you attend an ophthalmology congress, what is it that you expect to gain? Does the opportunity to mingle with the elite inspire you to pay your congress fee, or do you want to learn new skills and improve your everyday practice? Certainly, people's motivations have been somewhat ambiguous in the past. With the style of the traditional meetings placing more emphasis on lecture-type presentations with no real discussion and less emphasis on the sharing of knowledge amongst participants, meeting attendees rarely had any input whatsoever.

Elsewhere, we focus on pharmaceutical therapies in ophthalmology. A bitter pill to swallow provides a good review of the medications most frequently used in an ophthalmologist's everyday practice and urges us to ask the question "Do we really know the side effects of the drugs we give our patients".

As always, please do keep your suggestions and article submissions coming in to Ophthalmology Times Europe.

Happy reading.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.